Kemstro Articles
Alkermes' addiction drug to enter Ph II in 2H
9 April 2009
Azur buys four drugs from UCB
19 January 2009
Four Actavis generics gets US FDA approval
3 March 2008
Pfizer's celecoxib to become Japan's first COX-2 inhibitor
30 October 2006
Daiichi FY2005 net income soars 39%
16 May 2005
XenoPort starts Ph I GERD drug
4 April 2005
Tokyo pharma stock market: week to April 9, 2001
10 April 2001
Novartis ties up with Cephalon in UK marketing pact
7 December 2000
Cephalon News
9 July 1998
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Medtronic's SynchroMed Pump Gains US Approval
8 July 1996
IMPACT OF SWEDISH REFERENCE PRICING PLAN
6 June 1994
IMPACT OF SWEDISH REFERENCE PRICING
10 January 1994
ATHENA OUTLINES BUSINESS STRATEGY
5 October 1992
Showing 1-16 of 16 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
